Business Standard

Suven Pharma Bottomline Down 36%

Image

BUSINESS STANDARD

Hyderabad-based Suven Pharmaceuticals has suffered a 35.82 per cent fall in bottomline for 2002-03 at Rs 5.26 crore compared with Rs 8.20 crore in the previous fiscal.

Sales rose to Rs 46.96 crore (Rs 42.57 crore). Earnings per share was Rs 11.97 on an equity base of Rs 4.40 crore. The fall in net profit is attributed to changes in product mix in favour of high-volume-low-value products.

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Apr 28 2003 | 12:00 AM IST

Explore News